EvergreenHealth is now accepting patients interested in participating in a national clinical research study on Alzheimer’s. The study, Imaging Dementia-Evidence for Amyloid Scanning (IDEAS), is the first Alzheimer’s-focused study EvergreenHealth has participated in.
Through the IDEAS study, researchers will monitor the progress of participating patients for a total of 12 months. In that time, researchers will look to see if PET scans can help identify the causes and symptoms of Alzheimer’s and dementia and provide insight into better treatment strategies for the disease. The study, which is led by the Alzheimer’s Association and managed by the American College of Radiology (ACR) and the American College of Radiology Imaging Network (ACRIN), is non-invasive , after the initial PET scan, patients can continue with their normal course of care.
“As a health system, we continually strive to be at the forefront of innovation and research. We are honored to offer our first Alzheimer’s disease research study, which alongside specialists and physicians across the country, will help provide important insights into ways we can improve treatments for those suffering from cognitive impairment and dementia,” Bob Malte, EvergreenHealth CEO, said in a press release. “We encourage all who are eligible to consider participating, as our clinical research is another way to advance our purpose of enriching the health and well-being of those we serve.”
Alzheimer’s disease currently affects 5.4 million individuals in the U.S., and that number is expected to increase three-fold over the next several decades, affecting a projected 14 million people by the year 2050, according to the Centers for Disease Control and Prevention.
While there currently is no cure for the progressive brain disease, researchers are working to find better and more effective ways to treat it. Through the IDEAS study, clinicians hope to learn if PET scans of amyloid plaques in patients’ brains can help them diagnose the cause of the cognitive impairment and make more informed treatment decisions.
Individuals interested in enrolling in the study must be Medicare beneficiaries ages 65 or older who have been diagnosed with a mild cognitive impairment or dementia. A head MRI or CT scan must also have been performed within 24 months prior to enrollment.
For more information about the study, or to enroll, contact an EvergreenHealth provider or visit www.evergreenhealth.com/alzheimers-clinical-trials.